The value of allogeneic and autologous hematopoietic stem cell transplantation in prognostically favorable acute myeloid leukemia with double mutant CEBPA

Blood

Volumn 122, Issue 9, 2013, Pages 1576-1582

  Schlenk, Richard F ^a   Taskesen, Erdogan ^b   Van Norden, Yvette ^b   Krauter, Jürgen ^c   Ganser, Arnold ^c   Bullinger, Lars ^a   Gaidzik, Verena I ^a   Paschka, Peter ^a   Corbacioglu, Andrea ^a   Göhring, Gudrun ^d   Kündgen, Andrea ^e   Held, Gerhard ^f   Götze, Katharina ^g   Vellenga, Edo ^h   Kuball, Juergen ⁱ   Schanz, Urs ^j   Passweg, Jakob ^k   Pabst, Thomas ^l   Maertens, Johan ^m   Ossenkoppele, Gert J ⁿ   Delwel, Ruud ^b   Döhner, Hartmut ^a   Cornelissen, Jan J ^b   Döhner, Konstanze ^a   Löwenberg, Bob ^b   more..

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c Department of Internal Medicine III (Hematology Oncology and Transfusion Medicine)   (Germany)

^d HANNOVER MEDICAL SCHOOL   (Germany)

^e HEINRICH HEINE UNIVERSITY   (Germany)

^f SAARLAND UNIVERSITY   (Germany)

^g UNIVERSITY OF MUNICH   (Germany)

^h UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

ⁱ UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^j UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^k UNIVERSITY HOSPITAL BASEL   (Switzerland)

^l UNIVERSITY OF BERN   (Switzerland)

^m UNIVERSITY HOSPITALS LEUVEN   (Belgium)

ⁿ ACADEMIC MEDICAL CENTER   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AZACITIDINE; CCAAT ENHANCER BINDING PROTEIN ALPHA;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER REGRESSION; CLINICAL EVALUATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MUTANT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL;

EID: 84888032250     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-05-503847     Document Type: Article

References (39)

1. Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of the haematopoietic and lymphoid tissues. 4th ed. Geneva, Switzerland: WHO Press; 2008.
2. Döhner H, Estey EH, Amadori S, et al; European LeukemiaNet. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115(3):453-474.
3. Pabst T, Eyholzer M, Fos J, Mueller BU. Heterogeneity within AML with CEBPA mutations; only CEBPA double mutations, but not single CEBPA mutations are associated with favourable prognosis. Br J Cancer. 2009;100(8):1343-1346.
4. Wouters BJ, Löwenberg B, Erpelinck-Verschueren CA, van Putten WL, Valk PJ, Delwel R. Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome. Blood. 2009;113(13):3088-3091.
5. Dufour A, Schneider F, Metzeler KH, et al. Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome. J Clin Oncol. 2010;28(4):570-577.
6. Green CL, Koo KK, Hills RK, Burnett AK, Linch DC, Gale RE. Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations. J Clin Oncol. 2010;28(16):2739-2747.
7. Hou HA, Lin LI, Chen CY, Tien HF. Reply to 'Heterogeneity within AML with CEBPA mutations; only CEBPA double mutations, but not single CEBPA mutations are associated with favorable prognosis'. Br J Cancer. 2009;101(4):738-740.
8. Taskesen E, Bullinger L, Corbacioglu A, et al. Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity. Blood. 2011;117(8):2469-2475.
9. Bereshchenko O, Mancini E, Moore S, et al. Hematopoietic stem cell expansion precedes the generation of committed myeloid leukemia-initiating cells in C/EBPalpha mutant AML. Cancer Cell. 2009;16(5):390-400.
10. Schlenk RF, Döhner K, Krauter J, et al; German-Austrian Acute Myeloid Leukemia Study Group. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med. 2008;358(18):1909-1918. (Pubitemid 351620111)
11. Fröhling S, Schlenk RF, Stolze I, et al. CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations. J Clin Oncol. 2004;22(4):624-633. (Pubitemid 41095065)
12. Preudhomme C, Sagot C, Boissel N, et al; ALFA Group. Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA). Blood. 2002;100(8):2717-2723.
13. Schlenk RF, Döhner K, Kneba M, et al; German-Austrian AML Study Group (AMLSG). Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B. Haematologica. 2009;94(1):54-60.
14. Mrózek K, Marcucci G, Nicolet D, et al. Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia. J Clin Oncol. 2012;30(36):4515-4523.
15. Lö wenberg B, van Putten W, Theobald M, et al; Dutch-Belgian Hemato-Oncology Cooperative Group; Swiss Group for Clinical Cancer Research. Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia. N Engl J Med. 2003;349(8):743-752. (Pubitemid 37010778)
16. Pabst T, Vellenga E, van Putten W, et al; Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON); German AML Study Group (AMLSG); Swiss Collaborative Group for Clinical Cancer Research (SAKK). Favorable effect of priming with granulocyte colony-stimulating factor in remission induction of acute myeloid leukemia restricted to dose escalation of cytarabine. Blood. 2012;119(23):5367-5373.
17. Vellenga E, van Putten W, Ossenkoppele GJ, et al; Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON); Swiss Group for Clinical Cancer Research Collaborative Group (SAKK). Autologous peripheral blood stem cell transplantation for acute myeloid leukemia. Blood. 2011;118(23):6037-6042.
18. Lö wenberg B, Pabst T, Vellenga E, et al; Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON) and Swiss Group for Clinical Cancer Research (SAKK) Collaborative Group. Cytarabine dose for acute myeloid leukemia. N Engl J Med. 2011;364(11):1027-1036.
19. Schlenk RF, Benner A, Hartmann F, et al; AML Study Group Ulm (AMLSG ULM). Risk-adapted postremission therapy in acute myeloid leukemia: results of the German multicenter AML HD93 treatment trial. Leukemia. 2003;17(8):1521-1528. (Pubitemid 36986953)
20. Schlenk RF, Döhner K, Mack S, et al. Prospective evaluation of allogeneic hematopoietic stem-cell transplantation from matched related and matched unrelated donors in younger adults with high-risk acute myeloid leukemia: German-Austrian trial AMLHD98A. J Clin Oncol. 2010;28(30):4642-4648.
21. Care RS, Valk PJ, Goodeve AC, et al. Incidence and prognosis of c-KIT and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemias. Br J Haematol. 2003;121(5):775-777. (Pubitemid 36718195)
22. Valk PJ, Bowen DT, Frew ME, Goodeve AC, Löwenberg B, Reilly JT. Second hit mutations in the RTK/RAS signaling pathway in acute myeloid leukemia with inv (16) Haematologica. 2004;89(1):106. (Pubitemid 38165863)
23. Verhaak RG, Goudswaard CS, van Putten W, et al. Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance. Blood. 2005;106(12):3747-3754. (Pubitemid 41739008)
24. Gray RJ. A class of k-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988;16(3):1141-1154.
25. Simon R, Makuch RW. A non-parametric graphical representation of the relationship of an event: application to responser versus nonresponder bias. Stat Med. 1984;3:35-44. (Pubitemid 14142275)
26. Mantel N, Byar D. 'Evaluation of response-time data involving transient states: An illustration using heart transplant data'. J Am Stat Assoc. 1974;69:81-86.
27. Andersen P, Gill RD. Cox's regression model for counting processes: A large sample study. Ann Stat. 1982;10:1100-1120.
28. Fröhling S, Schlenk RF, Krauter J, et al. Acute myeloid leukemia with deletion 9q within a noncomplex karyotype is associated with CEBPA loss-of-function mutations. Genes Chromosomes Cancer. 2005;42(4):427-432. (Pubitemid 40271285)
29. Gorin NC, Labopin M, Frassoni F, et al. Identical outcome after autologous or allogeneic genoidentical hematopoietic stem-cell transplantation in first remission of acute myelocytic leukemia carrying inversion 16 or t (8;21): a retrospective study from the European Cooperative Group for Blood and Marrow Transplantation. J Clin Oncol. 2008;26(19):3183-3188.
30. Kuwatsuka Y, Miyamura K, Suzuki R, et al. Hematopoietic stem cell transplantation for core binding factor acute myeloid leukemia: t (8;21) and inv (16) represent different clinical outcomes. Blood. 2009;113(9):2096-2103.
31. Schlenk RF, Benner A, Krauter J, et al. Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup. J Clin Oncol. 2004;22(18):3741-3750. (Pubitemid 41102131)
32. Marcucci G, Mrózek K, Ruppert AS, et al. Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t (8;21) differ from those of patients with inv (16): a Cancer and Leukemia Group B study. J Clin Oncol. 2005;23(24):5705-5717.
33. Forman SJ, Rowe JM. The myth of the second remission of acute leukemia in the adult. Blood. 2013;121(7):1077-1082.
34. Burnett AK, Goldstone A, Hills RK, et al. Curability of patients with acute myeloid leukemia who did not undergo transplantation in first remission [published online ahead of print February 25, 2013]. J Clin Oncol.
35. Watson M, Buck G, Wheatley K, et al. Adverse impact of bone marrow transplantation on quality of life in acute myeloid leukemia patients; analysis of the UK Medical Research Council AML 10 trial. The UK Medical Research Council AML 10 trial. Eur J Cancer. 2004;40:971-978. (Pubitemid 38496252)
36. Messerer D, Engel J, Hasford J, et al; German AML Intergroup. Impact of different postremission strategies on quality of life in patients with acute myeloid leukemia. Haematologica. 2008;93(6):826-833. (Pubitemid 351835978)
37. Cornelissen JJ, Gratwohl A, Schlenk RF, et al. The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach. Nat Rev Clin Oncol. 2012;9(10):579-590.
38. Khera N, Storer B, Flowers ME, et al. Nonmalignant late effects and compromised functional status in survivors of hematopoietic cell transplantation. J Clin Oncol. 2012;30(1):71-77.
39. Ashfaq K, Yahaya I, Hyde C, et al. Clinical effectiveness and cost-effectiveness of stem cell transplantation in the management of acute leukaemia: a systematic review. Health Technol Assess. 2010;14(54):iii-iv, ix-xi, 1-141.